antibody

Anti-Dopamine beta-Hydroxylase, C-Terminus

MBS502023

0.1 mL

345 USD

polyclonal

sheep

nonconjugated

human, mouse

Antibody

Anti-Dopamine beta-Hydroxylase, C-Terminus

Dopamine beta-Hydroxylase, C-Terminus, Human

dopamine beta-hydroxylase; Dopamine beta-hydroxylase; dopamine beta-hydroxylase; dopamine beta-hydroxylase (dopamine beta-monooxygenase); Dopamine beta-monooxygenase

DBH

DBH; DBH; DBM

DOPO_HUMAN

Polyclonal

Sheep

Human, mouse, and non-human primate

617

Specific for the ~75k DBH protein in Western blots.

Affinity Purified (Prepared from sheep serum by affinity purification using a Sulfo-Link column matrix to which the peptide immunogen was coupled.)

100 ul in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 ug per ml BSA and 50% glycerol. Adequate amount of material to conduct 10-mini Western Blots.

For long term storage -20 degree C is recommended. Stable at -20 degree C for at least 1 year.

Western Blot (WB)

Quality Control: Western blots performed on each lot. WB: 1:1000

Antigen: Peptide from the C-terminal region of human dopamine beta-hydroxylase (DBH), conjugated to keyhole limpet hemocyanin (KLH). Immunogen Information: Synthetic peptide corresponding to amino acid residues from the C-terminal region conjugated to KLH. Immunogen Species: Human

Species Reactivity Note: The antibody has been directly tested for reactivity in Western blots with human, mouse, and non-human primate tissue. Biological Significance: DBH catalyzes the conversion of dopamine to norepinephrine and serves as a marker of noradrenergic cells. DBH antibodies and antibodies for other markers of catecholamine biosynthesis are widely used as markers for dopaminergic and noradrenergic neurons in a variety of applications including depression, schizophrenia, Parkinson's disease and drug abuse (Kish et al., 2001; Zhu et al., 2000; Zhu et al., 1999). The expression of DBH is also elevated during stress (Sabban and Kvetnansky, 2001).

Affinity purified sheep polyclonal antibody

Kish SJ, Kalasinsky KS, Derkach P, Schmunk GA, Guttman M, Ang L, Adams V, Furukawa Y, Haycock JW (2001) Striatal dopaminergic and serotonergic markers in human heroin users. Neuropsychopharmacology 24:561-567. Sabban EL, Kvetnansky R (2001) Stress-triggered activation of gene expression in catecholaminergic systems: dynamics of transcriptional events. Trends Neurosci 24:91-98. Zhu MY, Klimek V, Haycock JW, Ordway GA (2000) Quantitation of tyrosine hydroxylase protein in the locus coeruleus from postmortem human brain. J Neurosci Meth 99:37-44. Zhu MY, Klimek V, Dilley GE, Haycock JW, Stockmeier C, Overholser JC, Meltzer HY, Ordway GA (1999) Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry 46:1275-1286.

116534900

NP_000778.3

NM_000787.3

P09172

75

Amine-derived Hormones Pathway (160983); Biogenic Amine Synthesis Pathway (198793); Catecholamine Biosynthesis Pathway (160984); Catecholamine Biosynthesis, Tyrosine = Dopamine = Noradrenaline = Adrenaline Pathway (413357); Catecholamine Biosynthesis, Tyrosine = Dopamine = Noradrenaline = Adrenaline Pathway (468235); Metabolism Pathway (477135); Metabolism Of Amino Acids And Derivatives Pathway (106169); Monoamine Transport Pathway (198851); Tyrosine Metabolism Pathway (82959); Tyrosine Metabolism Pathway (325)

The protein encoded by this gene is an oxidoreductase belonging to the copper type II, ascorbate-dependent monooxygenase family. It is present in the synaptic vesicles of postganglionic sympathetic neurons and converts dopamine to norepinephrine. It exists in both soluble and membrane-bound forms, depending on the absence or presence, respectively, of a signal peptide. [provided by RefSeq, Jul 2008]

Function: Conversion of dopamine to noradrenaline. Catalytic activity: 3,4-dihydroxyphenethylamine + ascorbate + O2 = noradrenaline + dehydroascorbate + H2O. Cofactor: Binds 1 PQQ per subunit.Binds 2 copper ions per subunit. Pathway: Catecholamine biosynthesis; (R)-noradrenaline biosynthesis; (R)-noradrenaline from dopamine: step 1/1. Subunit structure: Homotetramer composed of two non-covalently bound disulfide-linked dimers. Subcellular location: Soluble dopamine beta-hydroxylase: Cytoplasmic vesicle secretory vesicle lumen. Cytoplasmic vesicle secretory vesicle chromaffin granule lumen. Cytoplasmic vesicle secretory vesicle membrane; Single-pass type II membrane protein. Cytoplasmic vesicle secretory vesicle chromaffin granule membrane; Single-pass type II membrane protein . Potential. Induction: Activity is enhanced by nerve growth factor (in superior cervical ganglia and adrenal medulla). Trans-synaptic stimulation with reserpine, acetylcholine and glucocorticoids. Polymorphism: There are two main alleles of DBH: DBH-A with Ala-318 and DBH-B with Ser-318. Involvement in disease: Dopamine beta-hydroxylase deficiency (DBH deficiency) [MIM:223360]: Characterized by profound deficits in autonomic and cardiovascular function, but apparently only subtle signs, if any, of central nervous system dysfunction.Note: The disease is caused by mutations affecting the gene represented in this entry. Sequence similarities: Belongs to the copper type II ascorbate-dependent monooxygenase family.Contains 1 DOMON domain. Sequence caution: The sequence AAH17174.1 differs from that shown. Reason: Erroneous initiation. The sequence CAA31631.1 differs from that shown. Reason: Erroneous initiation. The sequence CAA31632.1 differs from that shown. Reason: Erroneous initiation. The sequence CAA68285.1 differs from that shown. Reason: Erroneous initiation.

0.1 mL

345 USD